Clinical features and outcomes of kidney transplant recipients with focal segmental glomerulosclerosis recurrence

Nephrology ◽  
2019 ◽  
Vol 24 (11) ◽  
pp. 1179-1188 ◽  
Author(s):  
Juliana B Mansur ◽  
Tainá V Sandes‐Freitas ◽  
Gianna M Kirsztajn ◽  
Marina P Cristelli ◽  
Gustavo F Mata ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Focal Segmental Glomerulosclerosis ◽  
Clinical Features ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Segmental Glomerulosclerosis

scholarly journals The Symptoms and Impact of Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Conceptual Model of the Patient Experience

2019 ◽  
Vol 36 (12) ◽  
pp. 3390-3408
Author(s):  
Marci English ◽  
Emily Hawryluk ◽  
Robert Krupnick ◽  
Mysore S. A. Kumar ◽  
Jason Schwartz
Keyword(s):  
Conceptual Model ◽  
Kidney Transplant ◽  
Focal Segmental Glomerulosclerosis ◽  
Patient Experience ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Segmental Glomerulosclerosis

The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis

2004 ◽  
Vol 43 (6) ◽  
pp. 1082-1090 ◽  
Author(s):  
Kui Huang ◽  
Maria E. Ferris ◽  
Kenneth A. Andreoni ◽  
Debbie S. Gipson
Keyword(s):  
Kidney Transplant ◽  
Focal Segmental Glomerulosclerosis ◽  
Differential Effect ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Segmental Glomerulosclerosis

scholarly journals Kidney Transplantation for Focal Segmental Glomerulosclerosis: Can We Prevent Its Recurrence? Personal Experience and Literature Review

2021 ◽  
Vol 11 (1) ◽  
pp. 93
Author(s):  
Hamza Naciri Bennani ◽  
Lionel Elimby ◽  
Florian Terrec ◽  
Paolo Malvezzi ◽  
Johan Noble ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Kidney Transplant ◽  
Focal Segmental Glomerulosclerosis ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Risk Of Recurrence ◽  
Segmental Glomerulosclerosis ◽  
Ckd Stage ◽  
Group 2 ◽  
Group 1

Background: Primary focal segmental glomerulosclerosis (FSGS) is associated with a high risk of recurrence after kidney transplantation with a major risk of graft loss despite preventive or curative treatments. Aim: to assess graft survival in FSGS kidney-transplant recipients and to compare those that had a relapse with those that had no relapse. Patients/Methods: we included 17 FSGS kidney-transplant recipients between January 2000 and January 2020, separated retrospectively into two groups (recurrences: n = 8 patients; no recurrences: n = 9 patients). FSGS recurrence was defined as having proteinuria of ≥3 g/g or urinary creatinine of ≥3 g/day. All patients received an induction therapy; maintenance immunosuppressive therapy at post-transplantation relied on tacrolimus/mycophenolate mofetil/steroids. In order to prevent or treat FSGS recurrence, patients received apheresis sessions plus rituximab. Results: FSGS recurrence rate was 47%. All patients that relapsed with a first graft also relapsed with subsequent grafts. Median time to recurrence was 3 (min: 1; max: 4745) days, despite rituximab/apheresis prophylaxis. Mean age was significantly lower in the relapsers (group 1) than in the non-relapsers (group 2); i.e., 47 ± 11 vs. 58 ± 9 years (p = 0.04). Time to progression to stage 5 chronic kidney disease (CKD) and young age at FSGS diagnosis were lower in group 1 compared to group 2; i.e., 5 (min: 1; max: 26) vs. 2 (min: 1; max: 26) years, and 16 (min: 4; max: 55) vs. 34 (min: 6; max 48) years, respectively. There was no difference between the two groups in terms of progression to CKD stage 5 on the native kidneys, averaging 7 years in both groups (p = 0.99). In group 1, seven patients received rituximab/apheresis prophylaxis, although this did not prevent the recurrence of FSGS. Conclusion: pretransplant prophylaxis with plasmapheresis/rituximab did not appear to reduce the risk of recurrence of primary FSGS on the graft, but could allow remission in the event of recurrence.

Sign in / Sign up

Export Citation Format

Share Document